Figure 2
Mice treated with MR16-1 are protected against bleomycin-induced dermal fibrosis. (A) Reduced dermal fibrosis in mice treated with MR16-1, injected with bleomycin. Representative hematoxylin and eosin-stained skin sections are shown. (B) Decreased dermal thickness in mice treated with MR16-1 (change by median(Q1,Q3) 1.00.7,1.2 versus 1.11.0,1.5 fold, P = 0.02). (C) Reduced accumulation of collagen in mice treated with MR16-1 following bleomycin treatment. Collagen fiber visualization by trichrome-staining skin sections is shown. (D) Reduced hydroxyprolin content in mice treated with MR16-1 following bleomycin treatment (change by median(Q1,Q3) 1.10.9,1.4 versus 1.61.2,2.0 fold, P = 0.007). (E) Lower myofibroblast counts in mice treated with MR16-1 following bleomycin treatment (change by median(Q1,Q3) 0.90.8,1.5 versus 1.51.3,2.5 fold, P = 0.005). Control mice were injected with NaCl, and the value for these mice was defined as 1; the results from the other groups were normalized to this value. Bars represent median(Q1,Q3); 36 mice were used for these experiments (12 per group). Ab, antibody.